| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
31,350,000 |
| Market
Cap: |
16.03(M) |
| Last
Volume: |
15,038 |
Avg
Vol: |
14,997 |
| 52
Week Range: |
$0.2246 - $0.648 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalyst Biosciences is a research and clinical development biopharmaceutical company. Co.'s complement portfolio consists of the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, improved albumin-fused Complement Factor I (CFI) molecule intended for prophylactic subcutaneous or intravitreal administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential component 3 degrader product candidate in preclinical development for the treatment of dry age-related macular degeneration. Co. has several engineered protease programs in discovery or early non-clinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
9,750 |
| Total Buy Value |
$0 |
$0 |
$0 |
$4,584 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
60,000 |
60,000 |
60,000 |
60,000 |
| Total Sell Value |
$950,777 |
$950,777 |
$950,777 |
$950,777 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
3 |
3 |
3 |
3 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barris Peter J |
10% Owner |
– – • |
2007-02-06 |
4 |
OE |
$0.08 |
$75 |
I/I |
1,000 |
2,000 |
|
- |
|
| Kramlich C Richard |
10% Owner |
– – • |
2007-02-06 |
4 |
OE |
$0.08 |
$75 |
I/I |
1,000 |
2,000 |
|
- |
|
| Newhall Charles W III |
10% Owner |
– – • |
2007-02-06 |
4 |
OE |
$0.08 |
$75 |
I/I |
1,000 |
2,000 |
|
- |
|
| Perry Mark W |
10% Owner |
– – • |
2007-02-06 |
4 |
OE |
$0.08 |
$75 |
I/I |
1,000 |
2,000 |
|
- |
|
| Desouza Errol B |
Director |
– • – |
2007-02-01 |
4 |
OE |
$0.08 |
$75 |
D/D |
1,000 |
2,000 |
|
- |
|
| Richard John P |
Director |
– • – |
2007-02-01 |
4 |
OE |
$0.08 |
$75 |
D/D |
1,000 |
5,333 |
|
- |
|
| Dunbar Geoffrey C |
VP Clin. Dev. & Reg. Affairs |
• – – |
2006-11-06 |
4 |
OE |
$1.75 |
$20,748 |
D/D |
11,856 |
34,458 |
|
- |
|
| Burrill Steven |
Director |
– • – |
2006-08-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
779,062 |
|
- |
|
| Nomura Phase4 Ventures Ltd |
Member of 13G Group |
– – – |
2006-04-18 |
4/A |
A |
$0.00 |
$0 |
I/I |
946,428 |
946,428 |
|
- |
|
| Nomura Phase4 Ventures Ltd |
Member of 13G Group |
– – – |
2006-04-18 |
4/A |
A |
$0.00 |
$0 |
D/D |
1,190,476 |
2,136,904 |
|
- |
|
| Nomura Phase4 Ventures Gp Ltd |
Member of 13G Group |
– – – |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
946,428 |
946,428 |
|
- |
|
| Nomura Phase4 Ventures Gp Ltd |
Member of 13G Group |
– – – |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,190,476 |
2,136,904 |
|
- |
|
| Nea Partners 10 L P |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| New Enterprise Associates 10 L P |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,913,512 |
3,263,512 |
|
- |
|
| Newhall Charles W III |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| Morris Peter |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| Kramlich C Richard |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| Trainor III Eugene A |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| Perry Mark W |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| Barrett M James |
Director |
– • • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,913,512 |
3,263,512 |
|
- |
|
| Euclidsr Associates, L.p. |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,509,401 |
1,510,080 |
|
- |
|
| Jones Elaine V |
Director |
– • – |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
1,880,829 |
371,748 |
|
- |
|
| Euclidsr Biotechnology Partners, L.p. |
10% Owner |
– – • |
2006-04-18 |
4 |
A |
$0.00 |
$0 |
D/D |
371,428 |
371,748 |
|
- |
|
530 Records found
|
|
Page 20 of 22 |
|
|
